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Abstract This prospective Phase II single-arm study
gathered data on the use of intensity-modulated radiother-
apy (IMRT) to deliver accelerated partial breast irradiation
(APBI). Four-year efficacy, cosmesis, and toxicity results
are presented. Between February 2004 and September
2007, 136 consecutive patients with Stage 0/I breast cancer
and negative margins C0.2 cm were treated on protocol.
Patients received 38.5 Gy in 10 equal fractions delivered
twice daily. Breast pain and cosmesis were rated by patient,
and cosmesis was additionally evaluated by physician per
Radiation Therapy Oncology Group (RTOG) criteria. The
National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI CTCAE v3.0) was used to grade
toxicities. 136 patients (140 breasts) with median follow-up
of 53.1 months (range, 8.9–83.2) were evaluated. Popula-
tion characteristics included median age of 61.9 years and
Tis (13.6 %), T1a (18.6 %), T1b (36.4 %), and T1c
(31.4 %). Kaplan–Meier estimates at 4 years: ipsilateral
breast tumor recurrence 0.7 %; contralateral breast failure
0 %; distant failure 0.9 %; overall survival 96.8 %; and
cancer-specific survival 100 %. At last follow-up, patients
and physicians rated cosmesis as excellent/good in 88.2
and 90.5 %, respectively; patients rated breast pain as
none/mild in 97.0 %. Other observations included edema
(1.4 %), telangiectasia (3.6 %), five cases of grade 1
radiation recall (3.6 %), and two cases of rib fractures
(1.4 %). This analysis represents the largest cohort and
longest follow-up of APBI utilizing IMRT reported to date.
Four-year results continue to demonstrate excellent local
control, survival, cosmetic results, and toxicity profile.
Keywords Accelerated partial breast irradiation  Breast
cancer  Breast-conserving therapy  Intensity-modulated
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Introduction
Breast-conserving therapy (BCT) of lumpectomy followed
by radiotherapy has disease-free and overall survivals
comparable to those of mastectomy, for ductal carcinoma
in situ (DCIS) and early stage invasive breast cancer [1–4].
The 5–7 weeks required for the current standard of care
whole breast irradiation (WBI) can be a significant deterrent
for patients who would otherwise be good candidates for
BCT [5–7]. Studies have investigated delivering a biologi-
cally equivalent radiation dose to the involved region over a
shortened time frame [8–44]. The rationale for irradiating
only a partial breast volume, including observations that a
majority of ipsilateral breast tumor recurrences (IBTR)
developed at or in the area of the tumor bed, has been
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thoroughly elaborated elsewhere [8, 9]. This alternative
treatment approach is commonly known as accelerated
partial breast irradiation (APBI).
Various techniques for APBI delivery have been
explored over the past decade, including interstitial (multi-
catheter) brachytherapy [10–15], single-entry brachyther-
apy using intracavitary devices such as MammoSite
[16–20], external beam radiotherapy (EBRT) utilizing
photons [21–37] or protons [38, 39], and intraoperative
radiotherapy (IORT) delivered as a single fraction at the
time of definitive surgery [40–43]. EBRT, specifi-
cally EBRT utilizing 3-dimensional conformal planning
(3D-CRT), has gained popularity due to its noninvasive
nature, decreased procedural trauma to the breast, ease of
adoption for most radiation treatment facilities, and its
suitability for most cases (in terms of tumor location and
breast volume) [8, 9, 44]. APBI using EBRT is associated
with a lower risk of seroma formation and infection than
APBI delivered by brachytherapy [44]. Compared to
brachytherapy and IORT techniques, 3D-CRT offers the
best target coverage and the most homogenous dose distri-
bution (i.e., minimizing ‘‘hot spots,’’ the amount of breast
tissue receiving radiation doses markedly exceeding the
prescription dose); potential drawbacks of 3D-CRT include
radiation exposure to a larger volume of the uninvolved
ipsilateral breast, heart, and lung tissue (to account for
tumor motion and setup variability), leading to a higher
integral dose (total energy deposited in the patient) [8, 44].
While 3D-CRT relies on physical wedges (also known
as blocks) to reduce the dose delivered by each treatment
beam to adjacent healthy tissue, intensity-modulated
radiotherapy (IMRT), a technique that might be considered
the next generation of 3D-CRT, enables rapid re-blocking
while the patient is being treated, thus allowing the radia-
tion oncologist to vary the size and intensity of treatment
beams to deliver spatially nonuniform doses that result in a
homogenous dose distribution at the target site. The high
precision and customizability afforded by IMRT has led to
superior clinical outcomes and reduced toxicities in pros-
tate (and other organs) irradiation compared to 3D-CRT
[45–53]; accordingly, IMRT has been adopted as a new
standard of care in prostate, head and neck, and central
nervous system irradiation. Several studies utilizing IMRT
to deliver WBI (including randomized, nonrandomized,
and single-arm prospective studies compared to historical
controls) have demonstrated dosimetric advantages of
IMRT over 3D-CRT with accompanying decreases in
incidence, duration, and severity of toxicities such as der-
matitis, pruritus, moist desquamation, edema (both acute
and chronic), and hyperpigmentation [48–53].
Despite the potential advantages of IMRT over 3D-
CRT, relatively few groups have investigated the use of
IMRT to deliver APBI. Among the pending large
randomized clinical trials directly comparing WBI to
adjuvant APBI (including GEC-ESTRO interstitial brach-
ytherapy, IMPORT Low, NSABP B-39/RTOG 0413, and
RAPID), only the British IMPORT Low study makes use
of IMRT. Since one key advantage of BCT over mastec-
tomy is the potential preservation of the appearance and
sensation of the breast, recent institutional reports of
adverse cosmesis and toxicity from APBI using 3D-CRT
[30, 32] have been received with concern. Early 3D-CRT
toxicities from B-39 were reassuringly low [27], leading
many to suppose that the adverse outcomes reported were
due to institutional practices or small sample size. How-
ever, the Canadian-based RAPID study has now reported
interim toxicity and cosmesis results, showing that APBI
delivered with 3D-CRT was associated with worse cos-
metic outcomes and late radiation changes at 3 years
compared to WBI [29].
This prospective, hypothesis-generating Phase II single-
arm study gathered dosimetric data and clinical outcomes of
APBI delivered with IMRT (APBIMRT). We previously
compared 56 APBIMRT plans from this trial to 3D-CRT
plans following B-39 dose constraints retrospectively con-
structed on the same cases [34]; IMRT improved normal
tissue sparing in the ipsilateral breast without compromising
treatment target coverage. This report presents the 4-year
disease control, cosmesis, and toxicity outcomes for the first
140 breasts treated on this Phase II study at our institutions.
Materials and methods
Patient population
Between February 2004 and September 2007, 150 con-
secutive patients with Stage 0/I breast cancer were pro-
spectively enrolled on an Institutional Review Board-
approved study of APBIMRT. Subsequently, 14 patients
were not treated with APBIMRT: 2 due to patient choice, 1
due to insurance concerns, and 11 due to technical ineli-
gibility. Of the 11 ineligible patients, 1 was ineligible
because the lumpectomy cavity could not be visualized on
planning scans for contouring, and the remaining either had
lumpectomy cavities deemed too large for APBI or the
cavities were so medial in location that the dose constraints
for the heart or the contralateral breast could not be met.
The remaining 136 patients (4 with bilateral disease) were
treated at 6 facilities in Colorado, USA. Internal retro-
spective review showed that 2/136 did not meet all eligi-
bility criteria but were treated according to protocol and
therefore included in this analysis.
The eligibility requirements were initially age
C45 years, Stage T1N0M0 (as defined by AJCC Cancer
Staging Manual, 6th edition), and negative margins
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C2 mm after final surgery (re-excision permitted). The
protocol was later amended to include patients C40 years
old and pure DCIS.
IMRT planning and treatment
Treatment technique, target volume and normal tissue
contouring, and dose constraints have been previously
reported in detail [34] and summarized here. The first 8
patients were treated to the prescribed dose of 34 Gy, and
the remaining patients to 38.5 Gy. Patients were treated
while supine in 10 equal fractions delivered twice daily
(with 6-h interfractional minimum) over 5 consecutive
days; 1 patient received treatment over 6 days and 2 over
9 days due to unplanned linear accelerator maintenance or
inclement weather. The clinical target volume (CTV) was
initially defined as the lumpectomy cavity ?2 cm for the
patients treated to 34 Gy, then decreased to lumpectomy
cavity ?1 cm when the prescribed dose was increased to
38.5 Gy; the planning target volume (PTV) was defined as
CTV ?1 cm. No respiratory gating or active breathing
control was used. The CTV was at least 0.5 cm from the
chest wall and the skin surface. The PTV/ipsilateral breast
volume ratio was generally limited to B20 %. Plans were
optimized so C95 % of the PTV received C95 % of the
prescribed dose. Heart exposure was limited to B5 % organ
volume receiving [5 % of the prescribed dose. Ipsilateral
lung exposure was initially limited to B15 % receiving
[30 % of the prescribed dose (n = 8), then reduced to
B10 % receiving[30 % of the prescribed dose (n = 123),
and eventually to B10 % receiving [20 % of the pre-
scribed dose for the remaining cases in this series after we
gained more experience with image-guided radiotherapy
(IGRT). IGRT utilizing nonmigrating fiducial markers [35]
was adopted after more than 100 cases and used to treat 32
breasts in this cohort. For breasts treated without IGRT,
treatment was set up to skin tattoos and verified with
orthogonal pair MV imaging, approved prior to the first
treatment and confirmed intermittently throughout the
treatment course. APBIMRT was completed prior to any
chemotherapy.
Cosmesis and toxicities
Cosmesis and toxicities were evaluated 4–6 weeks after
treatment completion, then every 3–4 months for 2 years;
protocol was later amended to encourage yearly follow-up
beyond 2 years. Patients were asked to rate breast pain as
none, mild, moderate or severe, and cosmesis as excellent,
good, fair or poor without further instructions. Cosmesis
was additionally evaluated by physician per RTOG criteria;
(presumed) surgical effects on cosmesis were not excluded.
The National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE v3.0) was used to
grade toxicities. Rib fractures were confirmed by 2D plain
films.
Statistical methods
Time intervals were calculated from completion of APBI
unless noted otherwise. IBTRs were defined as the recur-
rence of cancer in the treated breast. Treatment failures
were dated to pathologic diagnosis of recurrence. Univar-
iate analysis was performed with the two-sample t test (age
and volumetric data were analyzed as continuous variables)
and the v2 test for independent observations and the paired
t test for repeated measures. Equality of variance was
verified with the F test to insure applicability of two-
sample t tests. Multivariate analysis was performed with
repeated measures ANOVA. Statistical significance was
defined as p B 0.05 with a = 0.05, p values were one-
sided (following standard v2 and F distributions).
Results
Patients
136 patients (140 breasts) were evaluated. The median
follow-up from APBI completion (for recurrence and sur-
vival) was 53.1 months (8.9–83.2).
MRI scanning
Bilateral MRI to rule out occult disease was not required
but was performed for the majority of patients. All 19 cases
with DCIS (100 %), 5 with invasive lobular (100 %), 3
with mixed invasive ductal and lobular histologies
(100 %), and 83 with invasive ductal histology with
accompanying DCIS component (80.7 %) had MRI
scanning.
Patient and treatment-related characteristics
Patient characteristics (Table 1) were generally favorable,
with median age of 61.9 years, median Tumor size of
0.95 cm, 76.4 % with a closest margin [0.5 cm, and
90.7 % estrogen receptor (ER) positive. Of note, over half
of the cases are classified as either ‘‘unsuitable’’ for APBI
outside of a clinical trial (n = 17, 16/17 cases were diag-
nosed at \50 years old, 2/17 cases of microscopically
multifocal DCIS spanning [3 cm) or ‘‘cautionary’’
(n = 66, 47/66 cases were diagnosed at ages 50–59, 11/66
ER negative) according to the APBI consensus guidelines
published in 2009 by the American Society for Radiation
Oncology (ASTRO) [44].
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Table 1 Patient characteristics
Characteristic All patients Stage I Stage 0
(n = 140 breasts) (n = 121 breasts) (n = 19 breasts)
Age at diagnosis (y)
Median (range) 61.9 (37.2–96.8a) 61.6 (37.2–96.8a) 62.4 (41.9–72.8)
Menopausal status at study entry (n)
Pre/Perimenopausal 26 (18.6 %) 22 (18.2 %) 4 (21.0 %)
Postmenopausal 114 (81.4 %) 99 (81.8 %) 15 (79.0 %)
Primary histology (n)
Ductal carcinoma in situ 19 (13.6 %) 19
Invasive ductal carcinoma 116 (82.9 %) 116 (95.9 %)
Invasive lobular carcinoma 5 (3.6 %) 5 (4.1 %)
Tumor grade (n) Histologic grade Nuclear grade
Low 61 (50.4 %) 5 (26.3 %)
Intermediate 40 (33.1 %) 7 (36.85 %)
High 16 (13.2 %) 7 (36.85 %)
Unavailable 4 (3.3 %)
Size of invasive tumors (cm)
Median (Range) 0.95 (0.1–2)
Presence of central necrosis (n)
Yes 10 (52.6 %)
No 9 (47.4 %)
Total span of DCIS (cm)
Median (Range) 0.5 (0.1–4)
Multifocal DCIS (n)
Yes 5 (26.3 %)
No 14 (73.7 %)
Margin size (cm)
Median (Range) 0.8 (0–2.1a) 0.9 (0–2.1a) 0.8 (0.2–1.5)
Estrogen receptor status (n)
Positive 127 (90.7 %) 111 (91.7 %) 16 (84.2 %)
Negative 13 (9.3 %) 10 (8.3 %) 3 (15.8 %)
HER2/neu status (n)
Positive 14 (10.0 %) 13 (10.0 %) 1 (5.2 %)
Negative 102 (72.9 %) 102 (84.3 %) 0 (0 %)
Unknown 24 (17.1 %) 6 (5.0 %) 18 (94.7 %)
ER negative and HER2 negative (n) 7 (5.0 %) 7 (5.8 %) 0 (0 %)
Sentinel nodes sampled (n)
Median (Range) 2 (0–11) 2 (1–11) 0 (0–3)
Total nodes sampled (n)
Median (Range) 2 (0–14) 3 (1–14) 0 (0–7)
T stage (n)
Tis 19 (13.6 %) 19 (100 %)
T1mic 6 (4.3 %) 6 (5.0 %)
T1a 20 (14.3 %) 20 (16.5 %)
T1b 51 (36.4 %) 51 (42.1 %)
T1c 44 (31.4 %) 44 (36.4 %)
N stage (n)
N0 136 (97.1 %) 117 (96.7 %) 19 (100 %)
N0(i?) 4 (2.9 %) 4 (3.3 %) 0 (0 %)
Bilateral breast MRI prior to enrollment (n) 117 (83.6 %) 98 (80.1 %) 19 (100 %)
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Treatment efficacy
Kaplan–Meier estimates of efficacy at 4 years: IBTR
0.7 %; contralateral breast failure 0 %; distant failure
0.9 %; overall survival 96.8 %; and cancer-specific sur-
vival 100 %. The one patient with subsequent IBTR was
originally diagnosed at age 44 with a 0.2 cm high-grade
DCIS tumor with comedonecrosis, margins C0.5 cm, and
ER and PR negative (HER2/neu not tested). The IBTR
(diagnosed * 14 months after treatment completion) was
also high-grade DCIS, located at C3.7 cm from the original
tumor by one author’s (T. K.) review of diagnostic imag-
ing, and verified to be outside the treatment volume (ref-
erencing the fiducial markers placed for IGRT), and
therefore an ‘‘elsewhere’’ failure [14, 54]. No true recur-
rence/marginal miss or ipsilateral nodal failures were
observed.
Cosmetic and pain results
Table 2 and Fig. 1 present the patient- and physician-rated
cosmesis as well as patient-rated pain in this study popu-
lation over time.
Patient- and physician-rated cosmesis outcomes asses-
sed at the same time points were categorized into excellent/
good and fair/poor and analyzed for agreement. There was
97 % agreement (n = 116) at 12 months and 92.2 %
(n = 77) at 24 months.
Univariate analysis
Univariate analysis showed no relationship between age at
diagnosis, re-excision, use of IGRT, ipsilateral breast vol-
ume (IB), PTV, and PTV/IB ratio to patient- or MD-rated
cosmesis or patient-reported pain at last follow-up. The
Table 1 continued
Characteristic All patients Stage I Stage 0
(n = 140 breasts) (n = 121 breasts) (n = 19 breasts)
ASTRO APBI Consensus [44] Category (n)
Suitable 57 (40.7 %) 57 (47.1 %) 0 (0 %)
Cautionary 67 (47.9 %) 51 (42.1 %) 16 (84.2 %)
Unsuitable 16 (11.4 %) 13 (10.7 %) 3 (15.8 %)
Adjuvant Treatment (n)
RT only 24 (17.1 %) 15 (12.4 %) 9 (47.4 %)
RT ? endocrine therapy (no chemotherapy) 97 (69.3 %) 87 (71.9 %) 10 (52.6 %)
RT ? chemotherapy (no endocrine therapy) 8 (5.7 %) 8 (6.6 %)
RT ? chemotherapy ? endocrine therapy 11 (7.9 %) 11 (9.1 %)
Time from end of RT to beginning of chemotherapy (month)
Median (Range) 0.4 (0.1–2.4)
Time from end of RT to beginning of endocrine therapy (month)
Median (Range) 0.5 (-1.9 to 4.6) 0.5 (-1.9 to 4.6) 0 (-0.9 to 2.0)
a As mentioned in the Materials/Methods section, 2 patients that did not meet all eligibility criteria but were treated on protocol were included in
the analysis and account for the age and margin size values listed in this table outside the range specified by the protocol
Table 2 Cosmesis and pain outcomes
Visita Patient-rated cosmesis Physician-rated cosmesis Patient-rated pain
nb Excellent/good nb Excellent/good nb None/mild
12 months 121 118 (97.5 %) 120 118 (98.3 %) 130 127 (97.7 %)
24 months 100 93 (93.0 %) 101 98 (97.1 %) 113 110 (97.7 %)
36 months 77 67 (87.0 %) 80 72 (90.00 %) 91 87 (95.6 %)
48 months 72 62 (86.1 %) 74 66 (89.2 %) 83 82 (98.8 %)
60 months 39 35 (90.8 %) 41 36 (87.8 %) 46 44 (95.7 %)
a From end of RT, closest follow-up within ±180 days to time point specified
b Breasts with evaluated cosmesis/pain
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lack of relationship between PTV and pain contrasts our
prior report [37]. However, the current analysis corrobo-
rates the statistically significant relationship between the
volume of the chest wall receiving [35 Gy and patient-
reported pain as previously discussed (results not shown).
Patients who reported moderate/severe pain at any point
during follow-up were proportionally more likely to report
fair/poor cosmesis at last follow-up (p = 0.008).
Patients who received endocrine therapy were propor-
tionally less likely to report pain at last follow-up
(p = 0.003). Patients who received endocrine therapy
exhibited a non-significant trend toward reporting excel-
lent/good cosmesis at last follow-up (p = 0.068).
Multivariate analysis
Multivariate analysis including time from RT and use of
endocrine therapy showed no relationship between either
factor and patient-reported cosmesis or pain. There was a
statistically significant decrease in physician-rated cosme-
sis over time (p = 0.003). This decrease remained signif-
icant when the model accounted for variations in endocrine
therapy, re-excision, and age, and appeared to stabilize
after 36 months from RT (Fig. 1; paired t test confirmed
loss of statistically significant difference between physi-
cian-rated cosmesis at 36 and 48 months). Due to the small
number of physician-evaluated cosmesis available at
60 months for comparison at this current time (n = 29),
this apparent stabilization requires future confirmation.
Treatment-related toxicities
Table 3 details the highest grade of toxicities reported for
each breast at any time following APBI. No grade 2? acute
skin toxicities and no heart or lung toxicities (of any grade)
were observed. At last follow-up, toxicities reported were
mild (1.4 %) edema, and mild (2.2 %) or moderate (1.4 %)
telangiectasia. The adverse event ‘‘radiation recall’’ corre-
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Moderate Mild None
Fig. 1 Cosmesis and pain
outcomes, legend: cosmesis:
marbled gray poor, striped gray
fair, solid light gray good, solid
dark gray excellent, pain:
striped gray moderate, solid
light gray mild, solid dark gray
none, excellent/good cosmesis:
dotted line with diamond
markers patient-rated, solid line
with square markers physician-
rated
Table 3 Treatment toxicities (highest grade reported for each breast)
Grade 0 Grade 1 Grade 2 Grade 3
Breast edema
(n = 138)
12 (90.6 %) 11 (8.0 %) 2 (1.4 %) 0 (0 %)
Telangiectasia
(n = 138)
129 (93.5 %) 7 (5.1 %) 2 (1.4 %) 0 (0 %)
Radiation recall
(n = 139)
134 (96.4 %) 5 (3.6 %) 0 (0 %) 0 (0 %)
Rib fracture
(n = 139)
137 (98.6 %) 0 (0 %) 2 (1.4 %) 0 (0 %)
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administered after completion of radiation, and was graded
according to CTCAE v3.0.
Discussion
This report is an update to previous publications [34–37]
and represents the largest cohort and longest follow-up of
APBIMRT reported to date. Four-year results continue to
demonstrate excellent local control, survival, cosmetic
results, and toxicity profile and support the continued use
and study of this technique. Table 4 offers an exploratory
comparison between this study and representative adjuvant
APBI studies that utilized brachytherapy, 3D-CRT, or
IMRT techniques.
Comparison of clinical outcomes to other APBI reports
As EBRT techniques for APBI delivery have become more
widely used, multiple institutions and cooperative groups
have published varying rates of late toxicity (Table 4). One
of the explanations offered by the RAPID study team for
their 3D-CRT APBI cosmesis results was lack of confor-
mality, i.e., the breast volume receiving high radiation
doses did not correspond precisely enough to the treatment
target volume. As we previously reported, in comparison to
3D-CRT, IMRT significantly increased conformality and
correspondingly improved normal ipsilateral tissue sparing;
the volume of ipsilateral lung and heart irradiated was
small with both techniques but decreased with IMRT [36].
The clinical implications of these findings were further
delineated by a later investigation demonstrating correla-
tion between patient-reported pain after APBIMRT and
chest wall volume receiving [35 Gy [37]. These findings
led us to hypothesize that improved normal tissue sparing
offered by IMRT may also improve clinical outcomes, such
as pain or cosmesis. Accordingly, in October 2007 (after
the entire patient series analyzed in this report had com-
pleted treatment), our institutional guidelines for APBI
using IGRT were amended to further reduce the PTV.
Leonard et al. [30] suggests that in the setting of larger
radiation doses over shorter time frames (hypofractiona-
tion), small differences in prescribed dose and dose dis-
tribution may result in dramatic differences in normal
tissue complication. Table 5 lists some key technical dif-
ferences between representative external beam APBI
studies, including the sizes of margin added to the lump-
ectomy cavity to form the PTV.
Both the Tufts and the University of Michigan studies
have reported associations between dose-volume data and
adverse clinical outcomes [30, 32]. Leonard et al. [30]
demonstrated statistically significant associations between
the percentage of breast volume receiving at least 100 %
(V100) and 50 % (V50) of the prescribed dose to subcu-
taneous fibrosis (p = 0.001 and 0.01), cosmesis (p = 0.02
and 0.04), and grade 2? toxicity (p = 0.009 and 0.003).
Jagsi et al. [32] also reported a significant association
between V100 and V50 to cosmesis (p = 0.02 and 0.002).
These findings suggest that it is not enough to simply
compare outcomes from different ABPI techniques (i.e.,
3D-CRT vs. IMRT, EBRT vs. brachytherapy); subtle
dosimetric considerations, e.g., differences between V100
and V50 reported by the 2 IMRT studies in Table 5, and
other factors, such as immobilization techniques, timing of
radiotherapy, the use of other adjuvant therapies, method-
ological differences in cosmesis assessment, statistical
anomalies associated with small sample sizes and/or short
follow-up, etc., may also contribute to variability in cos-
mesis and late toxicities.
The IBTR rate and clinical outcomes reported by this
study are comparable to outcomes of other APBI series
(Table 4). One theoretical concern regarding the improved
tissue sparing offered by IMRT is a potential increase in
marginal failures, but marginal failures were not observed
in this study population. Whether IMRT offers clinical
advantages such as less severe late toxicities over other
APBI techniques still requires testing in a randomized
setting.
MRI scanning in patient series
The role of MRI scanning in the management of breast
cancer is highly controversial and variable throughout the
world. Some studies have demonstrated that MRI identified
ipsilateral and/or contralateral occult disease and changed
APBI eligibility in 8.8 % [55] to 12.9 % [56] of prospec-
tively screened clinical candidates. MRI scanning to con-
firm suitability for breast conservation was not required by
this study but is commonly utilized by breast surgeons in
our region. A detailed analysis for (or against) the routine
use of MRI in determining APBI eligibility, including
whether it is cost-effective, and whether it has a clinically
significant impact on long term APBI outcomes, is outside
the scope of this paper. Nevertheless, it may be worth
noting that this study is the only one among published
EBRT APBI studies [10, 21–37] to report extensive use of
breast MRI scanning in the diagnostic workup of the
patient series. The effect of MRI on patient selection could
partially account for the low IBTR rate (0.7 %) we
observed.
Patient selection for APBI
APBI has gained popularity not only for its convenience to
patients, but also with the increasing recognition that in
cancer care, the more expansive treatment approach is not


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Breast Cancer Res Treat (2013) 140:119–133 129
123
always better. APBI has always—conceptually as well as
in published data—relied on proper selection, typically of
cases with clinicopathologic factors associated with low
risk for recurrence, and encompass patients whose treat-
ment options may include not only conventional WBI but
observation as well (although it should be noted that a
subgroup of patients in which RT does not reduce locore-
gional recurrence has yet to be identified [57, 58]). The
optimal patient population for APBI remains controversial,
as evidenced by the different sets of guidelines offered by
ASTRO, The Groupe Europe´en de Curiethe´rapie and
European Society for Therapeutic Radiology and Oncology
(GEC-ESTRO), the American Society of Breast Surgeons,
and the American Brachytherapy Society, as well as the
numerous retrospective studies questioning the merits of
these guidelines [44, 59–63].
The results reported here provide early confirmation of the
importance of proper patient selection and also suggest that
some patients deemed ‘‘cautionary’’ or even ‘‘unsuitable’’
may ultimately be appropriate for APBI. Although the
ASTRO consensus guidelines established a population of
patients ‘‘suitable’’ for APBI outside a clinical study [44], we
continue to treat *98 % of our institutional APBI cases on
study and closely monitor the outcomes. Of note, this study is
one of a few APBI studies utilizing EBRT to include syn-
chronous (or metachronous) bilateral disease. Since the
protocol limited the dose to the contralateral breast to less
than 3 % of the prescribed dose, there was minimal dose
overlap between the 2 breasts, and therefore bilateral treat-
ment with APBIMRT was technically feasible.
The debate over the clinical role of APBI is not likely to
be resolved until results are available from the large ran-
domized clinical trials. Nevertheless, the favorable local
control and late toxicity profiles detailed in this report
continue to support APBIMRT as a promising treatment
option worthy of further investigation. With the increasing
attention to cost-effective health resource allocation, the
greater cost of IMRT (relative to the 3D-CRT technique)
may partially account for the lack of trials investigating the
use of IMRT to deliver APBI. A careful comparison of
outcomes from patients treated with APBI using 3D-CRT
and IMRT—that specifically addresses whether the dosi-
metric advantages afforded by IMRT translates into mean-
ingful clinical benefit—is a prerequisite for any meaningful
cost-effectiveness analysis between 3D-CRT and IMRT. It
should be noted, however, that APBIMRT has been shown
to cost substantially less than single-catheter APBI tech-
niques [64], and still remains attractive compared to con-
ventional WBI over 6 weeks, or even hypofractionated WBI
over 4 weeks, in terms of cost to payers [64], impact on
departmental resources [65], and presumably overall societal
cost, even more so when decreased transportation costs and
time off from work are taken into account.
We previously demonstrated that IMRT provides
excellent treatment target coverage while generally
reducing the volume of ipsilateral breast, chest wall, lung,
and heart exposed to high doses [36], and that increased
pain correlated with larger chest wall and overall volumes
receiving [75 % of the prescribed dose [37]. This report
provides a significant update with a greater number of
patients and longer follow-up that is especially relevant in
the current context of discrepant cosmesis and toxicity
reported by various APBI studies utilizing EBRT. Our
currently enrolling Phase III randomized study will include
a direct comparison of clinical outcomes of patients treated
with APBI-using 3D-CRT and IMRT techniques.
Disclosures None.
Funding source Department of Radiation Oncology, Rocky
Mountain Cancer Centers.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini
A, Aquilar M, Marubini E (2002) Twenty-year follow-up of a
randomized study comparing breast-conserving surgery with
radical mastectomy for early breast cancer. N Engl J Med
347:1227–1232
2. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M,
Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up
of a randomized trial comparing total mastectomy, lumpectomy,
and lumpectomy plus irradiation for the treatment of invasive
breast cancer. N Eng J Med 347:1233–1241
3. EORTC Breast Cancer Cooperative Group, EORTC Radiother-
apy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van
Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fen-
timan IS, Bartelink H, Rutgers EJ (2006) Breast-conserving
treatment with or without radiotherapy in ductal carcinoma-
in situ: ten-year results of European Organisation for Research
and Treatment of Cancer randomized phase III trial 10853—a
study by the EORTC Breast Cancer Cooperative Group and
EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387
4. Solin LJ, Fourquet A, Vicini FA, Taylor M, Olivotto IA, Haffty
B, Strom EA, Pierce LJ, Marks LB, Bartelink H, McNeese MD,
Jhingran A, Wai E, Bihjker N, Campana F, Hwang WT (2005)
Long-term outcome after breast-conservation treatment with
radiation for mammographically detected ductal carcinoma
in situ of the breast. Cancer 103:1137–1146
5. Gilligan MA, Kneusel RT, Hoffmann RG, Greer AL, Nattinger
AB (2002) Persistent differences in sociodemographic determi-
nants of breast conserving treatment despite overall increased
adoption. Med Care 40:181–189
6. Nattinger AB, Kneusel RT, Hoffmann RG, Gilligan MA (2001)
Relationship of distance from a radiotherapy facility and initial
breast cancer treatment. J Natl Cancer Inst 93:1344–1346
130 Breast Cancer Res Treat (2013) 140:119–133
123
7. Nattinger AB, Hoffmann RG, Kneusel RT, Schapira MM (2000)
Relation between appropriateness of primary therapy for early-
stage breast carcinoma and increased use of breast-conserving
surgery. Lancet 356:1148–1153
8. Offersen BV, Overgaard M, Kroman N, Overgaard J (2009)
Accelerated partial breast irradiation as part of breast conserving
therapy of early breast carcinoma: a systematic review. Radiother
Oncol 90:1–13
9. NSABP B-39/RTOG 0413 protocol. https://members.nsabp.pitt.
edu/B39_Protocol.pdf. Accessed 9 Jan 2013
10. Polga´r C, Fodor J, Major T, Ne´meth G, Lo¨vey K, Orosz Z,
Sulyok Z, Taka´csi-Nagy Z, Ka´sler M (2007) Breast-conserving
treatment with partial or whole breast irradiation for low-risk
invasive breast carcinoma: 5-year results of a randomized trial.
Int J Radiat Oncol Biol Phys 69:694–702
11. Hattangadi JA, Powell SN, MacDonald SM, Mauceri T, Anc-
ukiewicz M, Freer P, Lawenda B, Alm El-Din MA, Gadd MA,
Smith BL, Taghian AG (2012) Accelerated partial breast irradi-
ation with low-dose-rate interstitial implant brachytherapy after
wide local excision: 12-year outcomes from a prospective trial.
Int J Radiat Oncol Biol Phys 83:791–800
12. Polga´r C, Major T, Fodor J, Sulyok Z, Somogyi A, Lo¨vey K,
Ne´meth G, Ka´sler M (2010) Accelerated partial-breast irradiation
using high-dose-rate interstitial brachytherapy: 12-year update of
a prospective clinical study. Radiother Oncol 94:274–279
13. Shah C, Antonucci JV, Wilkinson JB, Wallace M, Ghilezan M,
Chen P, Lewis K, Mitchell C, Vicini F (2011) Twelve-year
clinical outcomes and patterns of failure with accelerated partial
breast irradiation versus whole-breast irradiation: results of a
matched-pair analysis. Radiother Oncol 100:210–214
14. Vicini FA, Antonucci JV, Wallace M, Gilbert S, Goldstein NS,
Kestin L, Chen P, Kunzman J, Boike T, Benitez P, Martinez A
(2007) Long-term efficacy and patterns of failure after acceler-
ated partial breast irradiation: a molecular assay-based clonality
evaluation. Int J Radiat Oncol Biol Phys 68:341–346
15. Chen PY, Vicini FA, Benitez P, Kestin LL, Wallace M, Mitchell
C, Pettinga J, Martinez AA (2006) Long-term cosmetic results
and toxicity after accelerated partial-breast irradiation: a method
of radiation delivery by interstitial brachytherapy for the treat-
ment of early-stage breast carcinoma. Cancer 106:991–999
16. Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker
A, White J, Hedberg P, Hebert M, Arthur D, Zannis V, Quiet C,
Streeter O, Silverstein M (2007) Five-year results: the initial clin-
ical trial of MammoSite balloon brachytherapy for partial breast
irradiation in early-stage breast cancer. Am J Surg 194:456–462
17. Beitsch PD, Wilkinson JB, Vicini FA, Haffty B, Fine R, Whit-
worth P, Kuerer H, Zannis V, Lyden M (2012) Tumor bed control
with balloon-based accelerated partial breast irradiation: inci-
dence of true recurrences versus elsewhere failures in the
American Society of Breast Surgery MammoSite Registry Trial.
Ann Surg Oncol 19:3165–3170
18. Khan AJ, Arthur D, Vicini F, Beitsch P, Kuerer H, Goyal S,
Lyden M, Haffty BG (2012) Six-year analysis of treatment-
related toxicities in patients treated with accelerated partial breast
irradiation on the American Society of Breast Surgeons Mam-
moSite Breast Brachytherapy registry trial. Ann Surg Oncol
19:1477–1483
19. Vicini FA, Keisch M, Shah C, Goyal S, Khan AJ, Beitsch PD,
Lyden M, Haffty BG (2012) Factors associated with optimal
long-term cosmetic results in patients treated with accelerated
partial breast irradiation using balloon-based brachytherapy. Int J
Radiat Oncol Biol Phys 83:512–518
20. Chao KK, Vicini FA, Wallace M, Mitchell C, Chen P, Ghilezan
M, Gilbert S, Kunzman J, Benitez P, Martinez A (2007) Analysis
of treatment efficacy, cosmesis, and toxicity using the Mammo-
Site breast brachytherapy catheter to deliver accelerated partial-
breast irradiation: The William Beaumont Hospital experience.
Int J Radiat Oncol Biol Phys 69:32–40
21. Pashtan IM, Recht A, Ancukiewicz M, Brachtel E, Abi-Raad RF,
D’Alessandro HA, Levy A, Wo JY, Hirsch AE, Kachnic LA,
Goldberg S, Specht M, Gadd M, Smith BL, Powell SN, Taghian
AG (2012) External beam accelerated partial-breast irradiation
using 32 Gy in 8 twice-daily fractions: 5 year results of a pro-
spective study. Int J Radiat Oncol Phys 84:e271–e277
22. Taghian AG, Alm El-Din M, Smith BL, Ancukiewicz M, Mac-
Donald SS, Katz A, Specht M, Hirsch A, Powell SN, Recht A
(2008) Interim results of a phase I/II trial of 3D-conformal
external beam accelerated partial breast irradiation in patients
with early breast cancer [Abstract]. Presented at the American
Society for Radiation Oncology 50th Annual Meeting, September
21–25, Boston. MA. Int J Radiat Oncol Phys 72(Suppl):S4
23. Formenti SC, Hsu H, Fenton-Kerimian M, Roses D, Guth A,
Jozsef G, Goldberg JD, Dewyngaert JK (2012) Prone accelerated
partial breast irradiation after breast-conserving surgery: five-year
results of 100 patients. Int J Radiat Oncol Biol Phys 84:606–611
24. Vicini F, Winter K, Wong J, Pass H, Rabinovitch R, Chafe S,
Arthur D, Petersen I, White J, McCormick B (2010) Initial effi-
cacy results of RTOG 0319: Three-dimensional conformal radi-
ation therapy (3D-CRT) confined to the region of the lumpectomy
cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol
Phys 77:1120–1127
25. Shah C, Wilkinson JB, Lanni T, Jawad M, Wobb J, Fowler A,
Wallace M, Chen P, Grillis IS, Vincini F (2012) Five-year out-
come and toxicities using 3-dimensional conformal external
beam radiation therapy to deliver accelerated partial breast irra-
diation. Clin Breast Cancer 12:259–263
26. Chen PY, Wallace M, Mitchell C, Grillis I, Kestin L, Fowler A,
Martinez A, Vicini F (2010) Four-year efficacy, cosmesis, and
toxicity using three-dimensional conformal external beam radia-
tion therapy to deliver accelerated partial breast irradiation. Int J
Radiat Oncol Biol Phys 76:991–997
27. Julian TB, Constantino JP, Vicini FA, White JR, Winter A,
Arthur DW, Kuske RR, Rabinovitch R, Curran WJ Jr, Wolmark
N (2011) Early toxicity results with 3D conformal external beam
therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated
partial breast irradiation (APBI) trial [Abstract]. Presented at the
American Society for Radiation Oncology 53rd Annual Meeting,
October 2–6, Miami Beach, FL. Int J Radiat Oncol Phys
81(Suppl):S7
28. Berrang TS, Olivotto I, Kim DH, Nichol A, Cho BC, Mohamed IG,
Parhar T, Wright JR, Truong P, Tyldesley S, Sussman J, Wai E,
Whelan T (2011) Three-year outcomes of a Canadian multicenter
study of accelerated partial breast irradiation using conformal
radiation therapy. Int J Radiat Oncol Biol Phys 81:1220–1227
29. Whelan TJ, Olivotto I, Parpia S, Berrang T, Kim D, Kong I,
Truong P, Cochrane B, Julian J, RAPID Trial Investigators
(2013) Interim toxicity results from RAPID: a randomized trial of
accelerated partial breast irradiation (APBI) using 3D conformal
external beam radiation therapy (3D CRT) [Abstract]. Presented
at the American Society for Radiation Oncology 54th Annual
Meeting, October 28–31, 2012, Boston, MA. Int J Radiat Oncol
Phys 85:21–22
30. Leonard KL, Hepel JT, Hiatt JR, Dipetrillo TA, Price LL, Wazer
DE (2013) The effect of dose-volume parameters and interfrac-
tion interval on cosmetic outcome and toxicity after 3-dimen-
sional conformal accelerated partial breast irradiation. Int J
Radiat Oncol Phys 85:623–629
31. Lewin AA, Derhagopian R, Saigal K, Panoff JE, Abitbol A,
Wieczorek DJ, Mishra V, Reis I, Ferrell A, Moreno L, Takita C
(2012) Accelerated partial breast irradiation is safe and effective
using intensity-modulated radiation therapy in selected early-
stage breast cancer. Int J Radiat Oncol Phys 82:2104–2110
Breast Cancer Res Treat (2013) 140:119–133 131
123
32. Jagsi R, Ben-David MA, Moran JM, Marsh RB, Griffith KA,
Hayman JA, Pierce LJ (2010) Unacceptable cosmesis in a pro-
tocol investigating intensity-modulated radiotherapy with active
breathing control for accelerated partial-breast irradiation. Int J
Radiat Oncol Biol Phys 76:71–78
33. Livi L, Buonamici FB, Simontacchi G, Scotti V, Fambrini M,
Compagnucci A, Paiar F, Scoccianti S, Pallotta S, Detti B, Ag-
resti B, Talamonti C, Mangoni M, Bianchi S, Cataliotti L, Mar-
razo L, Bucciolini M, Biti G (2010) Accelerated partial breast
irradiation with IMRT: new technical approach and interim
analysis of acute toxicity in a phase III randomized trial. Int J
Radiat Oncol Biol Phys 77:509–515
34. Leonard CE, Carter DL, Kercher J et al (2007) Prospective trial
of accelerated partial breast intensity-modulated radiotherapy. Int
J Radiat Oncol Biol Phys 67:1291–1298
35. Leonard CE, Tallhamer M, Johnson T, Hunter K, Howell K,
Kercher J, Widener J, Kaske T, Paul D, Sedlacek S, Carter (2010)
Clinical experience with image-guided radiotherapy in an accel-
erated partial breast intensity-modulated radiotherapy protocol.
Int J Radiat Oncol Biol Phys 76:234–528
36. Rusthoven KE, Carter DL, Howell K, Kercher JM, Henkenberns
P, Hunter KL, Leonard CE (2008) Accelerated partial-breast
intensity-modulated radiotherapy results in improved dose dis-
tribution when compared with three-dimensional treatment-
planning techniques. Int J Radiat Oncol Biol Phys 70:296–302
37. Reeder R, Carter DL, Howell K, Henkenberns P, Tallhamer M,
Johnson T, Kercher J, Widner J, Kaske T, Paul D, Sedlacek S,
Leonard CE (2009) Predictors for clinical outcomes after accel-
erated partial breast intensity-modulated radiotherapy. Int J
Radiat Oncol Biol Phys 74:92–97
38. Kozak KR, Smith BL, Adams J, Kornmehl E, Katz A, Gadd M,
Specht M, Hughes K, Gioioso V, Lu HM, Braaten K, Recht A,
Powell SN, DeLaney TF, Taghian AG (2006) Accelerated partial-
breast irradiation using proton beams: initial clinical experience.
Int J Radiat Oncol Biol Phys 66:691–698
39. Wang X, Amos RA, Zhang X, Taddei PJ, Woodward WA,
Hoffman KE, Yu TK, Tereffe W, Oh J, Perkins GH, Salehpour
M, Zhang SX, Sun TL, Gillin M, Buchholz TA, Strom EA (2011)
External-beam accelerated partial breast irradiation using multi-
ple proton beam configurations. Int J Radiat Oncol Biol Phys
80:1464–1472
40. Leonardi MC, Ivaldi GB, Santoro L, Lazzari R, Ferrari A, Morra
A, Caldarella P, Burgoa L, Bassi FD, Sangalli C, Rotmensz N,
Luini A, Veronesi U, Orecchia R (2012) Long-term side effects
and cosmetic outcome in a pool of breast cancer patients treated
with intraoperative radiotherapy with electrons as sole treatment.
Tumori 98:324–330
41. Vaidya JS, Wenz F, Bulsara M, Joseph D, Tobias JS, Keshtgar M,
Flyger H, Massarut S, Alvarado M, Saunders C, Eiermann W,
Metaxas M, Sperk E, Sutterlin M, Brown D, Esserman L,
Roncadin M, Thompson A, Dewar JA, Holtveg H, Pigorsch S,
Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I,
Corica T, Williams NR, Baum M (2012) Targeted intraoperative
radiotherapy for early breast cancer: TARGIT-A Trial-updated
analysis of local recurrence and first analysis of survival
[Abstract]. Presented at the 35th annual San Antonio breast
cancer symposium, December 4–8, San Antonio, TX. Cancer
Research 72(Suppl):100s–101s
42. Beal K, Sacchini V, Zelefsky M, Rogers KH, McCormick B
(2012) Five year update on intraoperative radiation therapy for
breast cancer [Abstract]. Presented at the American Society for
Radiation Oncology 53rd Annual Meeting, October 2–6, Miami
Beach, FL. Int J Radiat Oncol Phys 81(Suppl):S241–S242
43. Vanderwalde NA, Jones EL, Kimple RJ, Moore DT, Klauber-
Demore N, Sartor CI, Ollila DW (2013) Phase 2 study of pre-
excision single-dose intraoperative radiation therapy for early-
stage breast cancers: six-year update with application of the
ASTRO accelerated partial breast irradiation consensus statement
criteria. Cancer 119:1736–1743
44. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA,
Hardenbergh PH, Julian TB, Marks LB, Todor DA, Vicini FA,
Whelan TJ, White J, Wo JY, Harris JR (2009) Accelerated partial
breast irradiation consensus statement from the American Society
for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys
74:987–1001
45. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson
A, Amols HI (2008) Incidence of late rectal and urinary toxicities
after three-dimensional conformal radiotherapy and intensity-
modulated radiotherapy for localized prostate cancer. Int J Radiat
Oncol Biol Phys 70:1124–1129
46. Sharma NK, Li T, Chen DY, Pollack A, Horwitz EM, Buyyou-
nouski MK (2011) Intensity-modulated radiotherapy reduces
gastrointestinal toxicity in patients treated with androgen depri-
vation therapy for prostate cancer. Int J Radiat Oncol Biol Phys
80:437–444
47. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stu¨rmer T,
Holmes JA, Reeve BB, Godley PA, Carpenter WR, Chen RC
(2012) Intensity-modulated radiation therapy, proton therapy, or
conformal radiation therapy and morbidity and disease control in
localized prostate cancer. JAMA 307:1611–1620
48. Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham
W, Vu TT, Truong P, Ackerman I, Paszat L (2008) A multicenter
randomized trial of breast intensity-modulated radiation therapy
to reduce acute radiation dermatitis. J Clin Oncol 26:
2085–2092
49. Barnett GC, Wilkinson J, Moody AM, Wilson CB, Sharma R,
Klager S, Hoole AC, Twyman N, Burnet NG, Coles CE (2009) A
randomised controlled trial of forward-planned radiotherapy
(IMRT) for early breast cancer: baseline characteristics and
dosimetry results. Radiother Oncol 92:34–41
50. Hardee ME, Raza S, Becker SJ, Jozsef G, Lymberis SC, Hoch-
man T, Goldberg JD, DeWyngaert KJ, Formenti SC (2012) Prone
hypofractionated whole-breast radiotherapy without a boost to the
tumor bed: comparable toxicity of IMRT versus a 3D conformal
technique. Int J Radiat Oncol Biol Phys 82:e415–e423
51. Freedman GM, Li T, Nicolaou N, Chen Y, Ma CC, Anderson PR
(2009) Breast intensity-modulated radiation therapy reduces time
spent with acute dermatitis for women of all breast sizes during
radiation. Int J Radiat Oncol Biol Phys 74:689–694
52. McDonald MW, Godette KD, Butker EK, Davis LW, Johnstone PA
(2008) Long-term outcomes of IMRT for breast cancer: a single-
institution cohort analysis. Int J Radiat Oncol Biol Phys 72:1031–1040
53. Harsolia A, Kestin L, Grills I, Wallace M, Jolly S, Jones C, Lala
M, Martinez A, Schell S, Vicini FA (2007) Intensity-modulated
radiotherapy results in significant decrease in clinical toxicities
compared with conventional wedge-based breast radiotherapy. Int
J Radiat Oncol Biol Phys 68:1375–1380
54. Recht A, Silver B, Schnitt S, Connolly J, Hellman S, Harris JR
(1985) Breast relapse following primary radiation therapy for
early breast cancer. I. Classification, frequency and salvage. Int J
Radiat Oncol Biol Phys 11:1271–1276
55. Ku¨hr M, Wolfgarten M, Sto¨lzle M, Leutner C, Holler T, Sch-
rading S, Kuhn W, Braun M (2011) Potential impact of preop-
erative magnetic resonance imaging of the breast on patient
selection for accelerated partial breast irradiation. Int J Radiat
Oncol Biol Phys 81:e541–e546
56. Dorn PL, Al-Hallaq HA, Haq F, Goldberg M, Abe H, Hasan Y,
Chmura SL (2013) A prospective study of the utility of magnetic
resonance imaging in determining candidacy for partial breast
irradiation. Int J Radiat Oncol Biol Phys 85:615–622
57. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M,
Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L,
132 Breast Cancer Res Treat (2013) 140:119–133
123
Whelan T, Wang Y, Peto R, Early Breast Cancer Trialists’ Col-
laborative Group (2011) Effect of radiotherapy after breast-con-
serving surgery on 10-year recurrence and 15-year breast cancer
death: meta-analysis of individual patient data for 10,801 women
in 17 randomised trials. Lancet 378:1707–1716
58. Mannino M, Yarnold JR (2009) Local relapse rates are falling
after breast conserving surgery and systemic therapy for early
breast cancer: can radiotherapy ever be safely withheld? Radio-
ther Oncol 90:14–22
59. Polga´r C, Van Limbergen E, Po¨tter R, Kova´cs G, Polo A, Lyczek
J, Hildebrandt G, Niehoff P, Guinot JL, Guedea F, Johansson B,
Ott OJ, Major T, Strnad V, GEC-ESTRO breast cancer working
group (2010) Patient selection for accelerated partial-breast
irradiation (APBI) after breast-conserving surgery: recommen-
dations of the Groupe Europeen de Curietherapie-European
Society for Therapeutic Radiology and Oncology (GEC-ESTRO)
breast cancer working group based on clinical evidence (2009).
Radiother Oncol 94:264–273
60. Board of Directors ASoBS (2011) Consenus statement for
accelerated partial breast irradiation. https://www.breastsurgeons.
org/statements/PDF_Statements/APBI.pdf. Accessed 14 June 2013
61. Breast Brachytherapy Task Group, ABS (2007) ABS Breast
Brachytherapy Task Group. http://www.americanbrachytherapy.
org/guidelines/abs_breast_brachytherapy_taskgroup.pdf. Accessed
14 June 2013
62. Vicini F, Arthur D, Wazer D, Chen P, Mitchell C, Wallace M,
Kestin L, Ye H (2011) Limitations of the American Society of
Therapeutic Radiology and Oncology Consensus Panel guide-
lines on the use of accelerated partial breast irradiation. Int J
Radiat Oncol Biol Phys 79:977–984
63. Shaitelman SF, Vicini FA, Beitsch P, Haffty B, Keisch M, Lyden
M (2010) Five-year outcome of patients classified using the
American Society for Radiation Oncology consensus statement
guidelines for the application of accelerated partial breast irra-
diation: an analysis of patients treated on the American Society of
Breast Surgeons MammoSite Registry Trial. Cancer 116:
4677–4685
64. Amin N, Konski AA (2013) Is hypofractionation the solution?
The financial implications of breast cancer treatments. Oncology
vol 27. April 15, 2013. http://www.cancernetwork.com/breast-
cancer/content/article/10165/2137308. Accessed 12 June 2013
65. Dwyer P, Hickey B, Burmeister E, Burmeister B (2010) Hypo-
fractionated whole-breast radiotherapy: impact on departmental
waiting times and cost. J Med Imaging Radiat Oncol 54:229–234
Breast Cancer Res Treat (2013) 140:119–133 133
123
